Reduced risk of bone metastasis for patients with breast cancer who use cox-2 inhibitors

Clinical Breast Cancer

Volumn 9, Issue 4, 2009, Pages 225-230

  Valsecchi, Matias E ^a   Pomerantz, Sherry C ^a   Jaslow, Rebecca ^a   Tester, William ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Adjuvant treatment; Celecoxib; Osteoclastic activity; Rofecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; VALDECOXIB;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; RISK REDUCTION;

EID: 73349098190     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.038     Document Type: Article

References (39)

1. Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer 2000; 36:476-482
2. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999; 6:71-73
3. Schapira DV, Theodossiou C, Lyman GH. The effects of NSAIDs on breast cancer prognostic factors. Oncol Rep 1999; 6:433-435
4. Khuder SA, Mutgi AB. Breast cancer and NSAID use: A meta-analysis. Br J Cancer 2001; 84:1188-1192
5. Cotterchio M, Kreiger N, Sloan M, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10:1213-1217
6. Johnson TW, Anderson KE, Lazovich D, et al. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:1586-1591 (Pubitemid 36020011)
7. Moorman PG, Grubber JM, Millikan RC, et al. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003; 14:915-922
8. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291:2433-2440
9. Zhang Y, Coogan PF, Palmer JR, et al. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: The case-control surveillance study revisited. Am J Epidemiol 2005; 162:165-170
10. Rahme E, Ghosn J, Dasgupta K, et al. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 2005; 5:159.
11. Blair CK, Sweeney C, Anderson KE, et al. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 2007; 101:191-197
12. Gallicchio L, Visvanathan K, Burke A, et al. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in washington county, MD. Int J Cancer 2007; 121:211-215
13. Kwan ML, Habel LA, Slattery ML, et al. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007; 18:613-620
14. Kirsh VA, Kreiger N, Cotterchio M, et al. Nonsteroidal antiinflammatory drug use and breast cancer risk: Subgroup findings. Am J Epidemiol 2007; 166:709-716
15. Ready A, Velicer CM, McTiernan A, et al. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 2008; 109:533-543
16. Gill JK, Maskarinec G, Wilkens LR, et al. Nonsteroidal antiinflammatory drugs and breast cancer risk: The multiethnic cohort. Am J Epidemiol 2007; 166:1150-1158
17. Agrawal A, Fentiman IS. NSAIDs and breast cancer: A possible prevention and treatment strategy. Int J Clin Pract 2008; 62:444-449
18. Harris RE, Beebe-Donk J, Doss H, et al. Aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs in cancer prevention: A critical review of nonselective COX-2 blockade. (review) Oncol Rep 2005; 13:559-583
19. Harris RE, Alshafie GA, Abou-Issa H, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60:2101-2103
20. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6:27.
21. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: Results of case control studies. Subcell Biochem 2007; 42:193-212.
22. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102
23. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080
24. Pritchard K, Whelan T. Clinical trial update: National cancer institute of canada. Breast Cancer Res 2005; 7:48-51.
25. Witters LM, Crispino J, Fraterrigo T, et al. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003; 26:S92-7.
26. Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002; 55:429-434
27. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62:632-635
28. Hiraga T, Myoui A, Choi ME, et al. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res 2006; 66:2067-2073
29. Singh B, Berry JA, Shoher A, et al. COX-2 involvement in breast cancer metastasis to bone. Oncogene 2007; 26:3789-3796
30. Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005; 90:2563-2570
31. Singletary SE, Allred C, Ashley P, et al. Revision of the american joint committee on cancer staging system for breast cancer. J Clin Oncol 2002; 20:3628-3636
32. Colleoni M, O'Neill A, Goldhirsch A, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000; 18:3925-3935
33. Lucci A, Krishnamurthy S, Singh B, et al. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 2008; 117:61-68
34. Subbaramaiah K, Howe LR, Port ER, et al. HER-2/neu status is a determinant of mammary aromatase activity in vivo: Evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 2006; 66:5504-5511
35. Oliveira VM, Piato S, Silva MA. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Res Treat 2006; 95:235-241
36. Freyer G, Debled M, Geay JF, et al. Celecoxib (ce) + exemestane (ex) versus placebo + ex in post-menopausal (PM) metastatic breast cancer (MBC) patients (pts): A double-blind phase III GINECO study. J Clin Oncol 2006; 24(18 suppl):19s (abstract 565).
37. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363
38. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19:10-17
39. Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. J Clin Oncol 2008; 26(15 suppl):6s (abstract LBA4).